Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: A meta-analysis

Lancet

Volumn 353, Issue 9157, 1999, Pages 964-969

  Kappos, Ludwig ^a   Moeri, David ^a   Radue, Ernst Wilhelm ^a   Schoetzau, Andreas ^a   Schweikert, Kati ^a   Barkhof, Frederik ^b   Miller, David ^c   Guttmann, Charles R G ^d   Weiner, Howard L ^d   Gasperini, Claudio ^f   Filippi, Massimo ^e  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; STEROID;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DISABILITY; DISEASE COURSE; EUROPE; FEMALE; HUMAN; IMAGE ENHANCEMENT; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; UNITED STATES;

EID: 0033586376     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)03053-0     Document Type: Article

References (36)

1. Poser C.M., Paty D.W., Scheinberg L.et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 13:1983;227-231.
2. Miller D.H., Grossmann R.I., Reingold S.C., McFarland H.F. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain. 121:1998;3-24.
3. Kappos L., Staedt D., Ratzka M.et al. Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis. Neuroradiology. 30:1988;299-302.
4. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 45:1995;1277-1285.
5. Simon J.H., Jacobs L.D., Campion M.et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol. 43:1998;79-87.
6. Miller D.H., Barkhof F., Nauta J.J.P. Gadolinium enhancement increases the sensitivity of MR in detecting disease activity in multiple sclerosis. Brain. 116:1993;1077-1094.
7. Kappos L., Städt D., Keil W., Ratzka M., Heitzer T., Schneiderbanger-Grygier S. An attempt to quantify magnetic resonance imaging in multiple scerosis - correlation with clinical parameters. Neurosurg Rev. 10:1987;133-135.
8. Katz D., Taubenberger J.K., Cannella B., McFarlin D.E., Raine C.S., McFarland H.F. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol. 34:1993;661-669.
9. Brück W., Bitsch A., Kolenda H., Brück Y., Stiefel M., Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol. 42:1997;783-793.
10. Grossman R.I., Gonzalez-Scarano F., Atlas S.W., Galetta S., Silberberg D.H. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology. 161:1986;721-725.
11. Barkhof F., Scheltens P., Frequin S.T.F.M.et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR. 159:1992;1041-1047.
12. Smith M., Stone L., Albert P.et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol. 33:1993;480-489.
13. O'Riordan J.I., Thompson A.J., Kingsley D.P.et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain. 121:1998;495-503.
14. Khoury S.J., Guttmann C.R.G., Orav E.j.et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology. 44:1994;2120-2124.
15. Filippi M., Paty D.W., Kappos L.et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology. 45:1995;255-260.
16. Koudriatseva T., Thompson A.J., Fiorelli M.et al. Gadolinium-enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurosurg Psychiatry. 67:1997;285-287.
17. Lossef N.A., Kingsley D.P.E., McDonald W.I., Miller D.H., Thompson A.J. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Mult Scler. 1:1996;218-222.
18. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
19. Filippi M., Rossi P., Campi A., Colombo B., Pereira C., Comi G. Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability. Am J Neuroradiol. 18:1997;1549-1556.
20. Truyen L., Barkhof F., Tas M.et al. Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase III therapeutical trials. Mult Scler. 2:1997;283-290.
21. Thorpe J.W., Kidd D., Moseley I.F.et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology. 46:1996;373-378.
22. Kidd D., Thorpe J.W., Kendall B.E.et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurosurg Psychiatry. 60:1996;15-19.
23. Pozzilli C., Bastianello S., Koudriavtseva T.et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 61:1996;251-258.
24. Hohol M., Guttmann C., Olek M.et al. Roquinimex (Linomide) treatment in secondary progressive and relapsing remitting multiple sclerosis: results from 48 week randomized, double-blind, placebo-controlled pilot studies. Neurology. 48:1997;A174.
25. Kappos L., Radue E.W., Dellas S., Hartard C., Hartung H.P., Haller P. 15± Deoxyspergualine (DSG) in the treatment of active multiple sclerosis: final analysis of the European multicenter study. Neurology. 46:1996;A410-411.
26. van Oosten B.W., Lai M., Hodkinson S.et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology. 48:1997;351-357.
27. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911.
28. Miller D.H., Barkhof F., Berry I.et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted Action Guidelines. J Neurol Neurosurg Psychiatry. 54:1991;683-688.
29. McCullagh P., Nelder J.A., eds. Generalized linear models. In: monographs on statistics and applied probability no 37. London: Chapman & Hall, 1989: 48-55, 107-14, 193-200.
30. Weinshenker B.G. The natural history of multiple sclerosis. Neurol Clin. 13:1995;119-146.
31. Whitaker J.N., McFarland H.F., Rudge P., Reingold S.C. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler. 1:1995;37-47.
32. Weinshenker B.G., Issa M., Baskerville J. Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology. 46:1996;1613-1619.
33. Molyneux P.D., Filippi M., Barkof F.et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis: a multi-centre longitudinal study. Ann Neurol. 43:1998;332-339.
34. Truyen L., van Waesnerge J.H.T.M., van Walderveen M.A.A.et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 47:1996;1469-1476.
35. Noseworthy J.H. Clinical scoring methods for multiple sclerosis. Ann Neurol. 36:1994;S80-85.
36. Barkhof F., Filippi M., Miller D.H., Tofts P.S., Kappos L., Thompson A.J. Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol. 244:1997;76-84.